Iovance and MaSTherCell announce new manufacturing services agreement in EU
Iovance Biotherapeutics and MaSTherCell, an Orgenesis subsidiary, announced the two companies have entered into a new three-year Manufacturing Services Agreement. MaSTherCell will manufacture TIL for Iovance’s European late-stage clinical trials in its commercial-ready cGMP manufacturing suites. October 18, 2018